ReachMD

ReachMD CME

Science EN ↓ Epizody: 526

Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, cardiology, women's health and more. And our CME library is continuously growing, every quarter.

Určitě navštivte web podcastu a podpořte jeho tvůrce: reachmd.com

Autor

ReachMD

Kategorie

Science

Web podcastu

reachmd.com

Nejnovější epizoda

24. srp 2026

Kde poslouchat?

Podcasty v aplikaci Replaio Radio Už brzy

Podcasty míří do aplikace už brzy. Nainstaluj si ji teď a jako první uvidíš úplně nový pohled na podcasty

Nainstaluj zdarma Android téměř 10 mil. stažení · hodnocení 4,8 iOS už brzy

Epizody

Safety in oHCM Therapy: How and When to Transition Treatment? 26.03.2026 10:46

CME credits: 1.00 Valid until: 19-05-2027 Claim your CME credit at https://reachmd.com/programs/cme/safety-in-ohcm-therapy-how-and-when-to-transition-treatment/56831/ This activity examines the evolving management of obstructive hypertrophic cardiomyopathy (oHCM), from persistent unmet needs to precision-based therapy with cardiac myosin inhibitors. Faculty review ongoing symptom burden and functi...

From Beta-Blockers to Myosin Inhibitors: Initial Decision-Making in Obstructive HCM 26.03.2026 11:15

CME credits: 1.00 Valid until: 19-05-2027 Claim your CME credit at https://reachmd.com/programs/cme/from-beta-blockers-to-myosin-inhibitors-initial-decision-making-in-obstructive-hcm/54843/ This activity examines the evolving management of obstructive hypertrophic cardiomyopathy (oHCM), from persistent unmet needs to precision-based therapy with cardiac myosin inhibitors. Faculty review ongoing sy...

From Evidence to Action: Integrating Emerging Myosin Inhibitors Into oHCM Treatment Plans 26.03.2026 5:15

CME credits: 1.00 Valid until: 19-05-2027 Claim your CME credit at https://reachmd.com/programs/cme/from-evidence-to-action-integrating-emerging-myosin-inhibitors-into-ohcm-treatment-plans/54841/ This activity examines the evolving management of obstructive hypertrophic cardiomyopathy (oHCM), from persistent unmet needs to precision-based therapy with cardiac myosin inhibitors. Faculty review ongo...

Redefining oHCM Care: Efficacy and Safety of Myosin Inhibitors 26.03.2026 5:30

CME credits: 1.00 Valid until: 19-05-2027 Claim your CME credit at https://reachmd.com/programs/cme/redefining-ohcm-care-efficacy-and-safety-of-myosin-inhibitors/54840/ This activity examines the evolving management of obstructive hypertrophic cardiomyopathy (oHCM), from persistent unmet needs to precision-based therapy with cardiac myosin inhibitors. Faculty review ongoing symptom burden and func...

Molecular Precision: How Myosin Inhibitors Redefine Control 26.03.2026 5:45

CME credits: 1.00 Valid until: 19-05-2027 Claim your CME credit at https://reachmd.com/programs/cme/molecular-precision-how-myosin-inhibitors-redefine-control/54839/ This activity examines the evolving management of obstructive hypertrophic cardiomyopathy (oHCM), from persistent unmet needs to precision-based therapy with cardiac myosin inhibitors. Faculty review ongoing symptom burden and functio...

When ß-Blockers Fall Short in oHCM: Time for a New Approach? 26.03.2026 5:45

CME credits: 1.00 Valid until: 19-05-2027 Claim your CME credit at https://reachmd.com/programs/cme/when-blockers-fall-short-in-ohcm-time-for-a-new-approach/54838/ This activity examines the evolving management of obstructive hypertrophic cardiomyopathy (oHCM), from persistent unmet needs to precision-based therapy with cardiac myosin inhibitors. Faculty review ongoing symptom burden and functiona...

Cracking the Code of Obstruction: Unmet Needs in oHCM 26.03.2026 4:30

CME credits: 1.00 Valid until: 19-05-2027 Claim your CME credit at https://reachmd.com/programs/cme/cracking-the-code-of-obstruction-unmet-needs-in-ohcm/54837/ This activity examines the evolving management of obstructive hypertrophic cardiomyopathy (oHCM), from persistent unmet needs to precision-based therapy with cardiac myosin inhibitors. Faculty review ongoing symptom burden and functional li...

Beyond Steroidal MRAs: The Nonsteroidal MRA Lens in HF 26.03.2026 15:00

CME credits: 0.25 Valid until: 26-03-2027 Claim your CME credit at https://reachmd.com/programs/cme/beyond-steroidal-mras-the-nonsteroidal-mra-lens-in-hf/49198/ In this brief podcast, Drs. Maria Pabon and Robert Mentz explore the evolving role of mineralocorticoid receptor antagonism in heart failure, with emphasis on patients who appear clinically stable yet remain at elevated biologic risk. They...

FcRn: Same Class, Different Paths—Spot Agent Differentiators 24.03.2026 5:30

CME credits: 1.00 Valid until: 24-03-2027 Claim your CME credit at https://reachmd.com/programs/cme/fcrn-same-class-different-pathsspot-agent-differentiators/54778/ This program examines treat-to-target (T2T) principles in generalized myasthenia gravis (gMG), emphasizing measurable goals such as minimal manifestation status (MMS) and minimal symptom expression (MSE). Faculty review validated tools...

The 2-Point Signal: Apply ≥2-Point Rule 24.03.2026 5:30

CME credits: 1.00 Valid until: 24-03-2027 Claim your CME credit at https://reachmd.com/programs/cme/the-2-point-signal-apply-2-point-rule/54777/ This program examines treat-to-target (T2T) principles in generalized myasthenia gravis (gMG), emphasizing measurable goals such as minimal manifestation status (MMS) and minimal symptom expression (MSE). Faculty review validated tools—including MG-ADL, Q...

Shared Goals, Shared Gains: Align With Patient Preferences 24.03.2026 6:00

CME credits: 1.00 Valid until: 24-03-2027 Claim your CME credit at https://reachmd.com/programs/cme/shared-goals-shared-gains-align-with-patient-preferences/54776/ This program examines treat-to-target (T2T) principles in generalized myasthenia gravis (gMG), emphasizing measurable goals such as minimal manifestation status (MMS) and minimal symptom expression (MSE). Faculty review validated tools—...

Escalate With Intention: Stepwise, Target-Anchored Moves 24.03.2026 5:00

CME credits: 1.00 Valid until: 24-03-2027 Claim your CME credit at https://reachmd.com/programs/cme/escalate-with-intention-stepwise-target-anchored-moves/54773/ This program examines treat-to-target (T2T) principles in generalized myasthenia gravis (gMG), emphasizing measurable goals such as minimal manifestation status (MMS) and minimal symptom expression (MSE). Faculty review validated tools—in...

The IgG Clock: Redose Using IgG Kinetics 24.03.2026 4:30

CME credits: 1.00 Valid until: 24-03-2027 Claim your CME credit at https://reachmd.com/programs/cme/the-igg-clock-redose-using-igg-kinetics/54772/ This program examines treat-to-target (T2T) principles in generalized myasthenia gravis (gMG), emphasizing measurable goals such as minimal manifestation status (MMS) and minimal symptom expression (MSE). Faculty review validated tools—including MG-ADL,...

When to Begin FcRn: Initiation Criteria, Key Evidence 24.03.2026 6:30

CME credits: 1.00 Valid until: 24-03-2027 Claim your CME credit at https://reachmd.com/programs/cme/when-to-begin-fcrn-initiation-criteria-key-evidence/54771/ This program examines treat-to-target (T2T) principles in generalized myasthenia gravis (gMG), emphasizing measurable goals such as minimal manifestation status (MMS) and minimal symptom expression (MSE). Faculty review validated tools—inclu...

Turning Flares Into Function: Flag Uncontrolled Disease 24.03.2026 4:30

CME credits: 1.00 Valid until: 24-03-2027 Claim your CME credit at https://reachmd.com/programs/cme/turning-flares-into-function-flag-uncontrolled-disease/54770/ This program examines treat-to-target (T2T) principles in generalized myasthenia gravis (gMG), emphasizing measurable goals such as minimal manifestation status (MMS) and minimal symptom expression (MSE). Faculty review validated tools—in...

Minimal By Design: Define MSE Endpoints 24.03.2026 5:00

CME credits: 1.00 Valid until: 24-03-2027 Claim your CME credit at https://reachmd.com/programs/cme/minimal-by-design-define-mse-endpoints/54769/ This program examines treat-to-target (T2T) principles in generalized myasthenia gravis (gMG), emphasizing measurable goals such as minimal manifestation status (MMS) and minimal symptom expression (MSE). Faculty review validated tools—including MG-ADL,...

Target Locked in gMG: Why T2T Matters 24.03.2026 6:15

CME credits: 1.00 Valid until: 24-03-2027 Claim your CME credit at https://reachmd.com/programs/cme/target-locked-in-gmg-why-t2t-matters/54768/ This program examines treat-to-target (T2T) principles in generalized myasthenia gravis (gMG), emphasizing measurable goals such as minimal manifestation status (MMS) and minimal symptom expression (MSE). Faculty review validated tools—including MG-ADL, QM...

Patient Voices and Provider Partnerships to Advance Cardio-Kidney-Metabolic Outcomes 19.03.2026 56:45

CME credits: 1.00 Valid until: 05-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/patient-voices-and-provider-partnerships-to-advance-cardio-kidney-metabolic-outcomes/56471/ Expert-curated slides on the fundamentals of cardio–kidney–metabolic (CKM) syndrome, emphasizing alignment of clinical guidelines with patient-centered care and strategies for identifying and addressing patie...

DKA in Focus: What the New Consensus Means for Practice 19.03.2026 15:45

CME credits: 0.25 Valid until: 19-03-2027 Claim your CME credit at https://reachmd.com/programs/cme/dka-new-consensus-practice/50979/ If widespread use of continuous ketone monitoring (CKM) devices is to be safe and effective in reducing the occurrence of diabetic ketoacidosis (DKA), it is important to establish clear ketone thresholds which notify CKM users when action on their part is required....

Shifting the Script: Personalizing Overactive Bladder Treatment in Complex Patients 13.03.2026 20:30

CME credits: 0.25 Valid until: 13-03-2027 Claim your CME credit at https://reachmd.com/programs/cme/shifting-the-script-personalizing-overactive-bladder-treatment-in-complex-patients/54125/ This audio-only podcast examines where contemporary approaches fall short when managing overactive bladder (OAB) in patients with complex clinical considerations, including women with persistent symptoms and me...

Applying Advances in Practice: Case-Based Look at Selecting Therapy for Cushing Syndrome 13.03.2026 16:30

CME credits: 0.25 Valid until: 13-03-2027 Claim your CME credit at https://reachmd.com/programs/cme/case-selecting-therapy-cushing-syndrome/50063/ Cushing syndrome has seen exciting advances over the last couple of years, but how do they translate into improved patient care? Let’s dig into a couple of cases and discuss! =

Translating Guidelines to Action in IgAN: Embracing a Simultaneous Dual-Concordant Approach 10.03.2026 5:00

CME credits: 1.00 Valid until: 10-03-2027 Claim your CME credit at https://reachmd.com/programs/cme/translating-guidelines-to-action-in-igan-embracing-a-simultaneous-dual-concordant-approach/54687/ IgA nephropathy (IgAN) remains the most common primary glomerulonephritis worldwide and a leading cause of chronic kidney disease and end-stage kidney disease in adolescents and young adults. The 2025 K...

Targeting Lower Proteinuria Levels: Shifting the Goalpost in IgAN 10.03.2026 6:30

CME credits: 1.00 Valid until: 10-03-2027 Claim your CME credit at https://reachmd.com/programs/cme/targeting-lower-proteinuria-levels-shifting-the-goalpost-in-igan/54686/ IgA nephropathy (IgAN) remains the most common primary glomerulonephritis worldwide and a leading cause of chronic kidney disease and end-stage kidney disease in adolescents and young adults. The 2025 KDIGO clinical practice gui...

Emerging Therapies in IgAN: Who Could Benefit the Most? 10.03.2026 7:30

CME credits: 1.00 Valid until: 10-03-2027 Claim your CME credit at https://reachmd.com/programs/cme/emerging-therapies-in-igan-who-could-benefit-the-most/54685/ IgA nephropathy (IgAN) remains the most common primary glomerulonephritis worldwide and a leading cause of chronic kidney disease and end-stage kidney disease in adolescents and young adults. The 2025 KDIGO clinical practice guideline upda...

Emerging Evidence: IgAN Disease-Modifying Agents 10.03.2026 8:00

CME credits: 1.00 Valid until: 10-03-2027 Claim your CME credit at https://reachmd.com/programs/cme/emerging-evidence-igan-disease-modifying-agents/54684/ IgA nephropathy (IgAN) remains the most common primary glomerulonephritis worldwide and a leading cause of chronic kidney disease and end-stage kidney disease in adolescents and young adults. The 2025 KDIGO clinical practice guideline updates re...